https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/clinoleic-baxter-healthcare-deerfield-il-usa-nutritional-supplement-toxicity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/clostridium-butyricum-tablets-bladder-urothelial-transitional-cell-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/cm313-sc-pemphigus-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/cm336-injection-autoimmune-bullous-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/cmop-chidamide-newly-diagnosed-peripheral-t-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/cmop-r-nhl 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/cohort-a-will-receive-an-initial-load-dose-of-8m-her2-positive-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/combination-of-antiplatelet-drugs-and-anticoagul-acute-myocardial-infarction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/combination-of-chemotherapy-and-immunotherapy-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/combination-of-targeted-biopsy-and-systematic-bi-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/combination-product-conventional-third-line-ther-colorectal-cancer-crc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/combination-therapy-comb-esophageal-squamous-cell-carcinoma-escc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/combinations-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/compound-diclofenac-sodium-acute-abdominal-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/conditioning-chemotherapy-followed-by-abtcr-anti-diffuse-large-b-cell-lymphoma-dlbcl 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/continuous-gastrocnemius-plane-block-with-ropiva-foot-ankle-injuries 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/contrast-enhanced-ultrasound-guided-core-biopsy-pancreatic-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/control-lidocaine-cream-atopic-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/controlled-low-central-venous-pressure-clcvp-tec-acute-kidney-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/conventional-roux-en-y-gastrojejunostomy-gastric-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/conventional-second-line-therapy-colorectal-cancer-crc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/conventional-third-line-therapy-colorectal-cancer-crc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/crystalline-cellulose-simple-occlusive-dressing-split-thickness-skin-graft-donor-sites 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/cs-101-beta-thalassemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/csii-diabetes-mellitus-type-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/ct-996-type-2-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/ct-ffr-assessment-coronary-artery-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/ct0590-car-t-cells-relapsed-and-or-refractory-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/cta101-diffuse-large-b-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/ctb-group-post-operative-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/cva-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/cyclophosphamide-acute-lymphoblastic-leukemia-pediatric 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/cyclosporin-a-acute-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/cyclosporine-a-bone-marrow-failure-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/cytarabine-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/cytokine-induced-killer-cells-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/endostar-esophageal 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/cytokine-induced-killer-cells-ovarian-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/da-epoch-nhl-with-hemophagocytic-lymphohistiocytosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dabigatran-etexilate-atrial-fibrillation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dalpiciclib-early-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dapagliflozin-10-mg-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dapagliflozin-diabetic-kidney-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dapagliflozin-treatment-group-atrial-fibrillation-af 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/daphne-extract-capsules-epithelial-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/daphnetin-lower-extremity-lymphedema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/daratumumab-antibody-mediated-rejection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/darolutamide-adt-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dasatinib-precursor-cell-lymphoblastic-leukemia-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dc-cik-immunotherapy-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dcb-docetaxel-carboplatin-versus-ec-followed-by-triple-negative-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/decitabine-acute-myelocytic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/decitabine-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/decitabine-acute-myeloid-leukemia-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/decitabine-plus-haag-regimen-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/decitabine-poor-graft-function 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/decitabine-thrombocytopenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/deep-sea-fish-oil-radiation-toxicity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dental-foam-biorepair-peribioma-oral-health 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dentoblis-gingivitis-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dermatophagoides-farinae-drops-group-1-atopic-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/desmopressin-patients-undergoing-endoscopic-sinus-surgery 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/determine-the-ed50-and-ed95-of-esketamine-intrauterine-polyp 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/deucravacitinib-palmoplantar-pustulosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dex-esk-older-patients 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dexamethasone-carcinoma-non-small-cell-lung 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dexamethasone-cataract 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dexamethasone-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dexamethasone-precursor-b-cell-lymphoblastic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dexlansoprazole-injection-effect-of-drugs 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dexlansoprazole-injection-safety-issues 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dexmedetomidine-aged 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dexmedetomidine-anxiety 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dexmedetomidine-benign-neoplasm-of-vocal-fold-glottis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dexmedetomidine-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dexmedetomidine-cesarean-section-affecting-fetus-or-newborn 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dexmedetomidine-children 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dexmedetomidine-elderly 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dexmedetomidine-esketamine-combination-aged 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dexmedetomidine-esketamine-combination-liver-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dexmedetomidine-esketamine-combination-obstructive-sleep-apnea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dexmedetomidine-heart-injuries 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dexmedetomidine-hydrochloride-for-injection-delirium 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dexmedetomidine-injection-coronary-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dexmedetomidine-obstructive-sleep-apnea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dexmedetomidine-old-age 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dexmedetomidine-older-patients 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dexmedetomidine-overall-survival 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dexmedetomidine-postoperative-cognitive-dysfunction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dexmedetomidine-postoperative-delirium-after-living-donor-renal 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dexmedetomidine-renal-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dexmedetomidine-renal-function 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dexmedetomidine-ropivacaine-pharmacological-action 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dextrometropine-and-0-9-sodium-chloride-solution-cataract 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/diagnostic-test-conventional-imaging-ct-mri-or-1-dll3-expressing-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/diagnostic-test-standard-of-care-imaging-68ga-ps-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/diane-35-pretreatment-polycystic-ovary-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/didroxyprogesterone-pregnancy-rate 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/different-degrees-of-adjustment-of-the-injection-exudative-age-related-macular-degeneration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/digoxin-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dipyridamole-50mg-tid-restless-leg-syndrome-due-to-uraemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/disitamab-vedotin-combined-with-zimberelizumab-biliary-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/disitamab-vedotin-her2-positive-gastric-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/disitamab-vedotin-rc48-upper-tract-urothelial-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dmts-taurine-multiple-sclerosis-ms-relapsing-remitting 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/docetaxel-esophageal-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/docetaxel-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/domestic-polysaccharide-superparamagnetic-iron-o-chronic-kidney-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/donor-lymphocyte-infusion-minimal-residual-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dopamine-renal-artery-stenosis-atherosclerotic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/doxorubicin-liposome-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dpp4-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dragon-boat-training-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/drug-coated-balloon-angioplasty-vertebral-artery-stenosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/drug-herpes-zoster 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/drug-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/drugs-and-stimulation-hearing-loss-sudden 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/duragtide-semaglutide-losenatide-tirzepatide-ebe-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/dynamometric-tension-assessment-incisional-hernia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/edaravone-dexborneol-acute-ischemic-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/edaravone-dexborneol-stroke-ischemic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/efgartigimod-telitacicept-1-week-interval-group-myasthenia-gravis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/egfr-antibody-nasopharyngeal-cancinoma-npc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/ejiao-compound-postpartum-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/eltrombopag-25-mg-oral-tablet-stem-cell-transplant-complications 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/endostar-brain-metastases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/endostar-esophageal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/endostar-nasopharyngeal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/endostatins-nasopharyngeal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/ensartinib-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/entecavir-0-5-mg-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/entecavir-liver-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/envafolimab-gastric-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/envafolimab-injection-gastrointestinal-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/envafolimab-metastatic-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/eprolidone-chronic-heart-failure-patients 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/erythropoietin-premature-infants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/escitalopram-oxalate-tablets-major-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/esketamine-0-2-mg-kg-cesarean-delivery 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/esketamine-1-elderly 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/esketamine-at-low-dose-insomnia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/esketamine-combined-with-dexmedetomidine-dexmedetomidine 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/favipiravir-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/autolus-therapeutics-plc/projects/auto2-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/esketamine-group-postherpetic-neuralgia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/esketamine-injection-group-0-25-mg-kg-esketamine 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/esketamine-post-induction-hypotension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/esketamine-postoperative-cognitive-dysfunction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/esketamine-postpartum-depression 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/esketamine-scoliosis-correction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/esophagectomy-esophageal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/etoposide-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/etoposide-non-hodgkin-s-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/etoposide-small-cell-lung-cancer-limited-stage 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/exenatide-circular-rna-lipid-nanoparticle-inject-t2dm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/exenatide-type-2-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/experimental-group-overweight-or-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/experimental-group-x-map-metastatic-colorectal-cancer-mcrc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/experimental-locally-advanced-rectal-cancer-larc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/experimental-tislelizumab-anlotinib-thymic-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/fcn-437c-fulvestrant-breast-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/febuxostat-refractory-gout 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/fecal-microbiota-insomnia-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/fecal-microbiota-transplantation-fecal-microbiota-transplantation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/fei-re-qing-granules-severe-pneumonia-caused-by-multidrug-resistant-g 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/ferric-carboxymaltose-injection-healthy-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/first-line-cohort-hepatocellular-carcinoma-hcc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/five-flavor-sophora-flavescens-enteric-coated-ca-radiation-induced-proctitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/flumatinib-flumatinib 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/fluoxetine-depression 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/fluoxetine-drug-hepatobiliary-malignancy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/folic-acid-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/forced-administration-of-furosemide-cytoreductive-surgery 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/fosaprepitant-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/fosinopril-chronic-kidney-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/foundational-treatment-acute-ischemic-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/ibi363-advan-ce-d 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/frpe-cells-age-related-macular-degeneration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/fruquintinib-and-everolimus-renal-cell-carcinoma-clear-cell-somatic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/ft-003-diabetic-macular-edema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/ft-003-neovascular-age-related-macular-degeneration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/fulzerasib-resectable-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/furmonertinib-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/g-csf-granulocyte-colony-stimulating-factor-granulocyte-colony-stimulating-factor-g-csf-mobi 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/g-scf-granulocyte-colony-stimulating-factor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/gallium-68-nodaga-jr11-neuroendocrine-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/ganoderma-lucidum-spore-carcinoma-non-small-cell-lung 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/gastrodin-injection-sensorineural-hearing-loss 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/gd007-low-dose-drug-group-moderate-severe-intrauterine-adhesions 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/gdmt-heart-failure-with-preserved-ejection-fraction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/gefarnate-coronary-artery-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/gemcitabine-and-oxaliplatin-gallbladder-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/gemcitabine-cisplatin-bladder-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/gentuximab-advanced-gastric-or-gastroesophageal-junction-ca 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/gilteritinib-acute-myeloid-leukemia-aml 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/ginkgo-biloba-extract-acute-ischemic-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/ginkgolide-intravenous-alteplase-thrombolysis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/gk01-injection-advanced-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/globin-reactivated-autologous-hematopoietic-stem-thalassemia-major 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/glucagon-like-peptide-1-receptor-agonist-semaglu-type-2-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/glycopyrronium-in-combination-with-tropisetron-postoperative-nausea-and-vomiting 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/glycosides-of-tripterygium-wilfordii-hook-gtw-henoch-sch-nlein-purpura-nephritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/gmcn-508b-lentired-transfusion-dependent-beta-thalassemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/gnrh-a-1m-adenomyosis-of-uterus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/gnrh-a-clinical-pregnancy-rate 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/gnrh-a-infertility-female 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/gnrha-cesarean-scar-diverticula 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/golidocitinib-irae 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/gonal-f-anovulation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/ly007-b-nhl 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/goserelin-allogeneic-haematopoietic-stem-cell-transplantat 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/gpc3-and-or-tgf-targeting-car-t-cells-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/gprc5d-car-t-cell-intravenous-infusion-plasma-cell-dyscrasias 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/group-a-fit-avapritinib-ia-regimen-acute-myeloid-leukemia-with-t-8-21-q22-q22 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/group-a-patients-with-pr-or-ctdna-positivity-aft-diffuse-large-b-cell-lymphoma-dlbcl 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/gst-hg121-tablets-pharmacokinetics 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/guideline-directed-medical-therapy-heart-failure-with-reduced-ejection-fraction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/gva-hdac-consolidation-gilteritinib-maintenance-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/half-dose-ticagrelor-acute-coronary-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/hb0043-acne-vulgaris 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/hcd19-il15-car-inkt-acute-lymphoblastic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/health-education-and-conservative-management-of-recurrent-acute-pancreatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/hellencare-alzheimer-s-disease-dementia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/hema-neotil01-leukemia-myeloid-acute 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/henagliflozin-proline-tablets-treatment-diabetes-type-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/heparin-and-rivaroxaban-liver-cirrhosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/heparin-sodium-cerebral-aneurysm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/her2-tumor-vaccine-adenocarcinoma-gej 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/hg204-mecp2-duplication-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/high-caloric-oral-nutritional-supplements-malnutrition-child 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/high-dose-anrikefon-laparoscopic-surgery 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/high-dose-vitamin-d2-softgels-chronic-kidney-disease-5d 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/high-energy-digestible-food-e2-caesarean-section 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/high-risk-experimental-group-adolescent-idiopathic-scoliosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/hipsc-rpe-cells-amd-age-related-macular-degeneration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/honghe-fujie-lotion-bacterial-vaginitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/hsk3486-chronic-renal-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/hsk3486-healthy-elderly-subjects 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/huang-long-zhi-xiao-granule-asthma-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/huangqi-guizhi-wuwu-decoction-diabetic-nephropathies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/human-adipose-derived-stem-cell-exosomes-acute-ischemic-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/human-amniotic-derived-mesenchymal-stem-cells-chronic-kidney-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/human-bcma-targeted-t-cells-injection-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/human-cord-blood-derived-mononuclear-cells-hcb-m-refractory-diabetic-foot 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/human-her2-targeted-car-m-cells-gastric-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/human-umbilical-mesenchymal-stem-cells-osteoarthritis-knee 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/humanized-cd7-car-t-cells-t-lymphoblastic-leukemia-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/humscs-combined-with-bovine-type-i-collagen-burn-wounds 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/hva-newly-diagnosed-acute-myeloid-leukemia-with-high 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/hy-2003-10-mg-ml-belkyra-and-placebo-moderate-or-severe-submental-fullness 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/hydrochloride-hydromorphone-flurbiprofen-axetil-enhanced-recovery-after-surgery 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/hydrochlorothiazide-captopril-nitrendipine-aspir-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/hydronidone-capsules-liver-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/hydroxychloroquine-sulfate-200-mg-tablet-atrial-fibrillation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/hydroxychloroquine-sulfate-primary-iga-nephropathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/hyperthermic-intraperitoneal-chemotherapy-hipec-gastric-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/hypofractionated-radiation-therapy-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/iac-regimen-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/ibr733-cell-injection-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/ici201-relapsed-refractory-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/icodextrin-peritoneal-dialysis-solution-peritoneal-dialysis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/icotinib-esophageal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/icotinib-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/ics-laba-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/il-15-armored-car-t-cells-relapsed-refractory-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/imatinib-progression-free-survival 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/immunological-agent-lung-cancer-metastatic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/immunotherapy-combined-with-chemotherapy-rectal-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/individual-atg-hematopoietic-stem-cell-transplantation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/indometacin-suppository-pancreatitis-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/induction-chemotherapy-and-immunotherapy-escc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/induction-chemotherapy-locally-advanced-nasopharyngeal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/induction-therapy-2-cycles-of-vpx-teniposide-pd-primary-central-nervous-system-lymphoma-pcnsl 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/induction-therapy-3-cycles-of-bvc-brentuximab-ve-cd30-peripheral-t-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/induction-therapy-pro-regimen-diffuse-large-b-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/inetetamab-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/infliximab-crohn-s-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/influence-of-propofol-sedation-on-memory-consoli-memory-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/infrared-ray-heat-treatment-liver-cirrhosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/infrared-thermography-chronic-obstructive-pulmonary-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/inotuzumab-ozogamicin-donor-lymphocyte-infusion-leukemia-lymphocytic-acute 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/insulin-acute-pancreatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/insulin-brain-injuries 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/insulin-gestational-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/insulin-injection-15-minutes-before-meals-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/insulin-lispro-injection-exenatide-injection-diabetes-mellitus-type-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/interleukin-2-beta-thalassemia-major 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/interleukin-7-and-chemokine-c-c-motif-ligand-19-b-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/intermediate-dose-cytarabine-in-combination-with-acute-myeloid-leukemia-aml 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/intracavernosal-administration-of-autologous-adr-erectile-dysfunction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/intraileal-infusion-incretins 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/intranasal-dexmedetomidine-esketamine-adenotonsillectomy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/intraoperative-radiation-therapy-in-malignant-ce-glioblastoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/intrathecal-administration-of-thiotepa-in-combin-leptomeningeal-metastasis-of-her2-positive-breas 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/intrauterine-lavage-therapy-intrauterine-adhesions 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/intravenous-anesthetic-induction-with-ciprofol-f-ciprofol 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/intravenous-esketamine-using-dixon-s-up-and-down-hepatic-neoplasm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/intravenous-immunoglobulin-guillain-barre-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/intravenous-immunoglobulins-human-guillain-barre-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/intravenous-infusion-iv-of-adebrelimab-ade-advanced-hepatocellular-carcinoma-hcc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/intravenous-thrombolysis-edaravone-ischemic-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/intravenous-tranexamic-acid-txa-infusion-spontaneous-intracranial-hemorrhage 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/iodixanol-kidney-failure-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/iort-laryngeal-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/iparomlimab-and-tuvonralimab-combined-with-lenva-gastric-or-gastroesophageal-junction-adenocarcin 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/iparomlimab-and-tuvonralimab-injection-in-combin-gastric-or-gastroesophageal-junction-adenocarcin 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/iparomlimab-and-tuvonralimab-injection-ql1706-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/iparomlimab-tuvonralimab-recurrent-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/ipt-plus-hd-tdcs-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/iptacopan-thrombotic-microangiopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/irinotecan-hydrochloride-liposome-injection-carb-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/irinotecan-liposomes-combined-with-cisplatin-car-neuroendocrine-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/iron-sucrose-human-erythropoietin-injection-vita-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/ivarmacitinib-tablet-polymyalgia-rheumatics-pmr 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/ivc-proliferative-diabetic-retinopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/ivonescimab-combined-with-chemotherapy-pretreated-pleural-mesothelioma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/ivosidenib-combined-with-venetoclax-and-azacitid-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/ixazomib-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/jak-inhibitor-dermatomyositis-adult-type 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/jianpi-lishi-jiedu-granules-colorectal-adenoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/jintrolong-low-dose-group-dwarfism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/jueyin-granules-psoriasis-vulgaris 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/jwcar129-safety-and-efficacy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/jy306-universal-nk-cell-injection-relapsed-or-refractory-hematological-malignancie 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/kang-fu-pen-cervical-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/kanglaite-head-and-neck-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/kava-piper-methysticum-extract-sleep 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/ketamine-intensive-care-unit 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/ketorolac-aortic-dissection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/keverprazan-h-pylori-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/lenalidomide-ptcl-nos 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/keverprazan-helicobacter-pylori-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/keverprazan-hydrochloride-tablets-high-dose-amox-helicobacter-pylori-infection-helicobacter-pylor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/kn046-esophageal-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/kunxian-capsule-diabetic-nephropathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/kxv01-tcr-lentinvivo-injection-advanced-solid-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/kxv01-tcr-lentinvivo-injection-advanced-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/lactated-ringers-solution-pancreatitis-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/lactulose-colon-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/lansoprazole-capsules-effect-of-drugs 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/lanthanum-polystyrene-sulphonate-powder-hyperphosphatemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/latanoprost-ocular-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/lbl-024-for-injection-triple-negative-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/lecanemab-10-mg-kg-alzheimer-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/lenalidomide-combined-with-g-chop-lo-chop-dlbcl-diffuse-large-b-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/lenalidomide-combined-with-rituximab-diffuse-large-b-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/lenalidomide-diffuse-large-b-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/lenvatinib-biliary-tract-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/lenvatinib-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/lenvatinib-hepatocellular-carcinoma-stage-iiia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/letrozole-intrauterine-insemination 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/letrozole-polycystic-ovary-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/leuprorelin-acetate-sintilimab-nsclc-stage-iii 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/leuprorelin-hematopoietic-stem-cell-transplantation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/levocarnitine-injection-renal-dialysis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/levofloxacin-acute-ischemic-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/levothyroxine-heart-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/lidocaine-heart-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/lifei-qingchang-granules-bronchiectasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/light-power-density-and-light-duration-40-mw-cm-healthy-adult-subjects 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/linperlisib-combination-with-obinutuzumab-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/liposomal-irinotecan-pancreatic-ductal-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/liposuction-anterior-cruciate-ligament-partial-rupture 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/liquid-biopsy-early-screening-liquid-biopsy-for-early-screening-of-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/liraglutide-ischemic-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/live-combined-bifidobacterium-and-lactobacillus-functional-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/live-combined-bifidobacteriun-lactobacillus-and-gastric-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/longidaza-bacterial-vaginosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/lorlatinib-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/low-dose-et019002-t-cells-b-cell-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/low-dose-oliceridine-oliceridine 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/low-dose-stem-cell-gel-group-burn-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/low-dose-ticagrelor-coronary-artery-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/low-dose-ticagrelor-platelet-reactivity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/lucar-e9d-or-lucar-e9k-cells-product-b-cell-non-hodgkin-lymphoma-recurrent-b-cell-non 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/lucar-g39p-cells-product-relapsed-and-refractory-b-cell-non-hodgkin-lymph 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/luspatercept-combined-with-low-dose-thalidomide-transfusion-dependent-thalassemia-patients 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/luspatercept-transfusion-dependent-non-severe-aplastic-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/lvivo-tavec200-product-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/maggot-debridement-therapy-diabetic-foot-ulcers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/mb07133-safety-issues 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/medical-management-acute-ischemic-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/medical-therapy-aortic-valve-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/medical-treatment-basilar-artery-occlusion 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/megestrol-acetate-oral-suspension-serplulimab-so-stage-iii-gastric-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/megestrol-yining-stage-iii-esophageal-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/menscs-transplantation-type-1-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/menstrual-blood-stem-cells-acute-lung-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/mesalazine-ulcerative-colitis-unspecified 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/metformin-endometrial-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/metformin-hydrochloride-sustained-release-tablet-osteoarthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/metformin-plus-pioglitazone-type-2-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/metformin-polycystic-ovary-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/metformin-type2-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/methimazole-graves-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/methotrexate-knee-osteoarthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/methotrexate-tablets-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/methylprednisolone-pulse-glomerulonephritis-iga 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/methylprednisolone-sodium-succinate-acute-ischemic-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/metoclopramide-or-mosapride-severe-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/mfolfoxiri-locally-advanced-rectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/mie-esophageal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/mimetic-granules-of-yiqi-wenjing-prescriptions-chemotherapy-induced-peripheral-neuropathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/mindfulness-meditation-based-on-brain-computer-i-atrial-fibrillation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/minimally-invasive-cholecystolithotomy-with-gall-gallstones 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/minocycline-intracerebral-hemorrhage 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/minocycline-ischemic-stroke-acute 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/mitoxantrone-hydrochloride-liposome-acute-myeloid-leukemia-aml 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/mitoxantrone-hydrochloride-liposome-injection-diffuse-large-b-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/mitoxantrone-hydrochloride-liposome-relapsed-refractory-acute-myeloid-leukaemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/mitoxantrone-liposome-ara-cytarabine-and-azaciti-acute-myeloid-leukaemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/mitoxantrone-liposome-relapsed-or-refractory-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/modified-beam-autologous-stem-cell-transplantation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/montelukast-sinusitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/mouse-nerve-growth-factor-cerebral-small-vessel-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/mtbf-regimen-relapse-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/multi-vitamin-carbohydrate-nausea-and-vomiting-aspiration-intraoperative 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/multiple-dose-of-ciprofloxacin-prophylaxis-kidney-stones 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/mycophenolate-mofetil-2-g-per-day-lymphocytic-myocarditis-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/n-acetylcysteine-nac-treatment-thrombotic-microangiopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/n-acetylcysteine-thrombotic-microangiopathies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/nab-paclitaxel-combined-with-carboplatin-epithelial-ovarian-carcinoma-stage-iii 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/nab-paclitaxel-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/nanoparticle-albumin-bound-paclitaxel-carboplati-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/narfurine-hydrochloride-orally-disintegrating-ta-improvement-of-pruritus-in-hemodialysis-patients 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/nbp-softgel-capsules-migraine 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/nedaplatin-nasopharyngeal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/nefecon-ambrisentan-iga-nephropathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/neoadjuvant-chemotherapy-combined-with-neoadjuva-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/neoadjuvant-chemotherapy-nact-hr-her2-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/neoadjuvant-therapy-gastric-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/neoadjuvant-therapy-hepatocellular-carcinoma-resectable 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/neoadjuvant-therapy-tcbhpy-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/nerve-block-with-liposomal-bupivacaine-and-intra-liposomal-bupivacaine 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/nggt002-injection-phenylketonurias 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/nifedipine-gits-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/nimotuzumab-combined-with-chemoradiotherapy-pancreatic-cancer-non-resectable 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/nimotuzumab-esophageal-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/nimotuzumab-esophageal-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/nimotuzumab-nasopharyngeal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/nimotuzumab-shr-1210-esophageal-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/nintedanib-dextromethorphan-idiopathic-pulmonary-fibrosis-ipf 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/nitroprusside-sodium-st-segment-elevation-myocardial-infarction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/nivolumab-injection-opdivo-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/nivolumab-ipilimumab-lung-cancer-non-small-cell 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/nk-cell-and-pd-1-antibody-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/nocardia-rubra-cell-wall-skeleton-diabetic-foot-ulcer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/normal-saline-placebo-disease-of-respiratory-system 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/normal-saline-postoperative-sleep-disturbance 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/nutrition-intervention-gastric-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/obinutuzumab-large-b-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/obinutuzumab-relapsed-or-refractory-b-cell-non-hodgkin-lympho 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/octacalcium-phosphate-tooth-extraction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/olverembatinib-myeloproliferative-neoplasm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/olverembatinib-philadelphia-positive-all 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/omc-and-pseudo-sdt-peripheral-arterial-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/ondansetron-hepatocellular-carcinoma-hcc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/online-adaptive-radiotherapy-cervical-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/optimal-hypoglycemic-treatment-type2-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/oral-carbohydrate-outfast-gastrointestinal-surgery 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/oral-chinese-herbal-medicine-of-clearing-heat-an-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/orelabrutinib-chronic-lymphocytic-leukemia-small-lymphocytic-l 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/orelabrutinib-combined-with-rituximab-regimen-marginal-zone-lymphoma-mzl 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/orelabrutinib-malt-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/orelabrutinib-marginal-zone-lymphoma-mzl 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/orelabrutinib-primary-central-nervous-system-hodgkin-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/organoid-guided-treatment-her2-negative-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/ornithine-aspartate-granule-non-alcoholic-fatty-liver-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/osimertinib-mesylate-tablets-and-anlotinib-hydro-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/osimertinib-non-small-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/oxaliplatin-calcium-folinic-acid-levofolinic-aci-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/oxaliplatin-rectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/oxycodone-and-parecoxib-sodium-combinations-oxycodone 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/paclitaxel-anthracycline-primary-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/paclitaxel-cisplatin-plus-5-fu-tcf-esophageal-cancer-stage-iib 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/paclitaxel-esophageal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/paclitaxel-or-docetaxel-cisplatin-or-carboplatin-uterine-cervical-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/paclitaxel-oral-solution-plus-subcutaneous-pertu-breast-cancers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/paclitaxel-polymeric-micelles-for-injection-and-locally-advanced-esophageal-squamous-cell-carcin 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/parecoxib-anti-inflammatory-agents-non-steroidal 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/parecoxib-emergence-delirium 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/parecoxib-pain-postoperative 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/parecoxib-postoperative-pain-management-pain-threshold-sho 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/patients-undergo-cvats-segmentectomy-non-small-cell-lung-cancer-stage-i 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/pc-sod-myocardial-reperfusion-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/pcar-019-anti-cd19-car-t-cells-acute-lymphocytic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/pcia-group-postoperative-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/pcsk9-inhibitor-intracranial-artery-stenosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/pd-1-and-dc-cik-cells-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/pd-1-and-dc-nk-cells-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/pd-1-antibody-sintilimab-multiple-primary-lung-cancers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/pd-1-ctla-4-dual-functional-antibody-bile-duct-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/pd-1-inhibitor-advanced-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/pd-1-pd-l1-monoclonal-antibody-plus-radiotherapy-locally-advanced-perihilar-cholangiocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/pd1-bcma-cart-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/pdd-regimen-doxorubicin-hydrochloride-iposome-bo-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/peak-value-anti-xa-venous-thromboembolism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/peg-rhg-csf-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/peg-somatropin-dwarfism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/peg-somatropin-growth-hormone-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/peg-somatropin-short-stature-children-born-small-for-gestationa 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/pegaspargase-combined-with-gemcitabine-etoposide-nk-t-cell-lymphoma-extranodal 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/peginterferon-2b-injection-condylomata-acuminata 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/peginterferon-2b-plus-an-anti-pd-1-advanced-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/pegylated-liposomal-doxorubicin-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/pembrolizumab-advanced-non-squamous-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/pembrolizumab-esophageal-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/pembrolizumab-injection-esophageal-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/pemetrexed-1-leptomeningeal-metastases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/pemetrexed-colorectal-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/pemetrexed-leptomeningeal-metastases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/pemetrexed-leptomeningeal-metastasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/penpulimab-lenalidomide-rituximab-gemcitabine-ox-lymphoma-large-b-cell-diffuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/percutaneous-transhepatic-biliary-stenting-with-malignant-obstructive-jaundice 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/personalized-mrna-tumor-vaccine-esophageal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/pharmacotherapy-diabetes-mellitus-type-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/pharmorubicin-or-pirarubicin-upper-tract-urothelial-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/pims-screening-pgt-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/pirarubicin-upper-tract-urothelial-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/placebo-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/placebo-covid-19-thalidomide 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/pld-and-carboplatin-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/plerixafor-relapsed-adult-all 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/tranilast-mucinoses 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/postoperative-adjuvant-lenvatinib-hepatocellular-carcinoma-hcc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/pramipexole-restless-legs-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/pre-operative-chemotherapy-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/pre-packaged-low-residue-diet-for-bowel-preparat-colonoscopy-bowel-preparation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/pre-packaged-low-residue-diet-for-bowel-preparat-ibd-inflammatory-bowel-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/prebiotic-fiber-supplement-loperamide-hydrochlor-chemotherapy-related-diarrhea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/prediction-model-arm-lung-cancer-screening 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/prediction-of-intraoperative-hypothermia-risk-intraoperative-hypothermia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/prednisolone-hiv-human-immunodeficiency-virus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/preoperative-hepatic-and-regional-arterial-chemo-colorectal-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/preoperative-lanreotide-treatment-acromegaly 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/preoperative-oral-carbohydrate-drink-gastric-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/prescribing-anapproved-drug-examination-irritable-bowel-syndrome-with-diarrhea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/prg2302-acute-lymphoblastic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/prizloncabtagene-autoleucel-non-hodgkin-s-b-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/probiotic-microbiota 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/probiotics-antibiotics-or-antidepressants-irritable-bowel-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/probiotics-ulcerative-colitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/profound-neuromuscular-blockade-profound-muscle-relaxation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/prophylactic-4scar19-cells-b-acute-lymphoblastic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/propofol-anesthesia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/prostate-biopsy-guided-by-psma-pet-ct-psma-pet-ct 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/prothrombin-complex-concentrate-human-cardiac-surgical-procedures 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/protocol-based-management-of-perioperative-antit-antithrombotic-therapy 2026-05-23 monthly 0.6